Galectin Therapeutics reported $1.48M in Selling and Administration Expenses for its fiscal quarter ending in June of 2024.





Selling And Administration Expenses Change Date
AbbVie USD 3.63B 54M Jun/2026
Bristol-Myers Squibb USD 1.83B 209M Jun/2026
Galectin Therapeutics USD 1.48M 110K Jun/2024
Gilead Sciences USD 1.52B 70M Jun/2026
Immunic USD 3.45M 451K Dec/2025
Incyte USD 351.73M 23.64M Jun/2026
Merck USD 2.89B 219M Jun/2026